Viridian Therapeutics, Inc. (VRDN) Reports Q4 Loss, Lags Revenue EstimatesZacks Investment Research • 02/27/25
Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2024 Financial ResultsBusiness Wire • 02/27/25
Viridian Therapeutics Highlights 2025 Corporate Priorities Following Positive Phase 3 Topline Data in Thyroid Eye DiseaseBusiness Wire • 01/08/25
Viridian: Positive Chronic TED Data Likely To Lead To BLA Filing In Second Half Of 2025 (Rating Upgrade)Seeking Alpha • 12/19/24
Viridian Therapeutics: Veligrotug De-Risked In TED With Hints Of DifferentiationSeeking Alpha • 12/18/24
Viridian Therapeutics Skyrockets After Besting Amgen In Thyroid Eye DiseaseInvestors Business Daily • 12/16/24
Viridian Therapeutics Announces Positive Topline Results from Veligrotug Phase 3 THRIVE-2 Clinical Trial in Patients with Chronic Thyroid Eye DiseaseBusiness Wire • 12/16/24
Viridian Therapeutics to Webcast Veligrotug Phase 3 THRIVE-2 Topline Results on December 16, 2024Business Wire • 12/13/24
Viridian Therapeutics Reports Third Quarter 2024 Financial Results and Recent Progress Including New FcRn DataBusiness Wire • 11/12/24
Viridian Therapeutics Announces Pricing of Upsized Public Offering of Shares of Common Stock and Preferred StockBusiness Wire • 09/12/24
Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred StockBusiness Wire • 09/10/24
Viridian Spikes On A 'Bull-Case Scenario' For Eye Drug Considered Amgen RivalInvestors Business Daily • 09/10/24
Viridian Therapeutics Announces Positive Topline Results from Veligrotug (VRDN-001) Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye DiseaseBusiness Wire • 09/10/24
Viridian Therapeutics to Webcast VRDN-001 Phase 3 THRIVE Topline Results on September 10, 2024Business Wire • 09/09/24
Viridian Therapeutics, Inc. (VRDN) Reports Q2 Loss, Lags Revenue EstimatesZacks Investment Research • 08/08/24
Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2024 Financial ResultsBusiness Wire • 08/08/24